{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:30:20Z","timestamp":1794439820747,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["Z20008"],"award-info":[{"award-number":["Z20008"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073335"],"award-info":[{"award-number":["82073335"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303804"],"award-info":[{"award-number":["82303804"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M730124"],"award-info":[{"award-number":["2023M730124"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["BMU2023PYJH009"],"award-info":[{"award-number":["BMU2023PYJH009"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e33816","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T15:47:17Z","timestamp":1719589637000},"page":"e33816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A case report of hemophagocytic lymphohistiocytosis induced by toripalimab plus chemoradiotherapy in cervical cancer"],"prefix":"10.1016","volume":"10","author":[{"given":"Shuhua","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-6745","authenticated-orcid":false,"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.heliyon.2024.e33816_bib1","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33816_bib2","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2665-9913(23)00064-4","article-title":"Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study","volume":"5","author":"McCarter","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33816_bib3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s43018-023-00572-5","article-title":"Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer","volume":"4","author":"Sung","year":"2023","journal-title":"Nat Cancer"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33816_bib4","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00277-020-04083-6","article-title":"A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study","volume":"99","author":"Yoon","year":"2020","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33816_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s40425-019-0598-9","article-title":"Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports","volume":"7","author":"Noseda","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33816_bib6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjh.16630","article-title":"Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review","volume":"189","author":"Dupr\u00e9","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e33816_bib7","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/cncr.30084","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in adults: relation to hemophagocytosis, characteristics, and outcomes","volume":"122","author":"Tamamyan","year":"2016","journal-title":"Cancer"},{"issue":"10434","key":"10.1016\/j.heliyon.2024.e33816_bib8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33816_bib9","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e33816_bib10","series-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2018"},{"issue":"9927","key":"10.1016\/j.heliyon.2024.e33816_bib11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33816_bib12","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/ajcp\/aqw076","article-title":"Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients","volume":"145","author":"Debaugnies","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"issue":"23","key":"10.1016\/j.heliyon.2024.e33816_bib13","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e33816_bib14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33816_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12051985","article-title":"Hemophagocytic lymphohistiocytosis associated with immunological checkpoint inhibitors: a pharmacovigilance study","volume":"12","author":"Diaz","year":"2023","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33816_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12877-023-04625-3","article-title":"Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review","volume":"24","author":"Zhai","year":"2024","journal-title":"BMC Geriatr."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33816_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005841","article-title":"Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature","volume":"11","author":"Liu","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33816_bib18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17331","article-title":"Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial","volume":"193","author":"Wang","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33816_bib19","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","article-title":"Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH steering committee of the histiocyte society","volume":"6","author":"Ehl","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33816_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjh.15506","article-title":"A comprehensive analysis of Lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis","volume":"183","author":"Bigenwald","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33816_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12185-019-02623-z","article-title":"Hemophagocytic lymphohistiocytosis as a harbinger of aggressive lymphoma: a case series","volume":"109","author":"Pasvolsky","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33816_bib22","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.cmi.2019.06.010","article-title":"PD-1 blockade with nivolumab-controlled Epstein-Barr virus infection and associated haemophagocytic lymphohistiocytosis: a case report","volume":"25","author":"Dong","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33816_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10875-024-01670-4","article-title":"Successful treatment of refractory EBV-associated hemophagocytic lymphohistiocytosis with combined emapalumab and PD-1 blockade","volume":"44","author":"Song","year":"2024","journal-title":"J. Clin. Immunol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33816_bib24","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1007\/s00277-023-05476-z","article-title":"An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis","volume":"102","author":"Xu","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.heliyon.2024.e33816_bib25","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.2147\/IDR.S372998","article-title":"Successful treatment of relapsed epstein-barr virus-associated hemophagocytic lymphohistiocytosis after allo-HSCT with PD-1 blockade: a case report","volume":"15","author":"Pi","year":"2022","journal-title":"Infect. Drug Resist."},{"issue":"9948","key":"10.1016\/j.heliyon.2024.e33816_bib26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.heliyon.2024.e33816_bib27","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33816_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008631","article-title":"Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer","volume":"12","author":"Xu","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33816_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33816_bib30","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33816_bib31","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(21)00366-5","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis","volume":"9","author":"Setiadi","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33816_bib32","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.cgh.2019.09.031","article-title":"Epstein-barr virus-positive mucocutaneous ulcers complicate colitis caused by immune checkpoint regulator therapy and associate with colon perforation","volume":"18","author":"Pugh","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33816_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/annonc\/mdw537","article-title":"Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression","volume":"28","author":"Takeshita","year":"2017","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33816_bib34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41571-021-00597-8","article-title":"Harnessing big data to characterize immune-related adverse events","volume":"19","author":"Jing","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33816_bib35","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10637-017-0534-0","article-title":"Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience","volume":"36","author":"Fujii","year":"2018","journal-title":"Invest. N. Drugs"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33816_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024098475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024098475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:56:35Z","timestamp":1778885795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024098475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":36,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024098475"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33816","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case report of hemophagocytic lymphohistiocytosis induced by toripalimab plus chemoradiotherapy in cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e33816"}}